Clinical Domain Working Groups

Neurotrophic receptor tyrosine kinase (NTRK) fusions are well-recognized oncogenic drivers in various pediatric and adult malignancies (PMID: 30333516, 31075511). Small-molecule kinase inhibitors targeting constitutive signaling by oncogenic NTRK fusions have been approved by the FDA for tumors harboring NTRK fusions (PMID: 30901551).

The NTRK expert panel will develop a sustainable process for systematic consensus review of fusions and associated secondary alterations in NTRK1, NTRK2, and NTRK3 genes that drive oncogenesis and response to targeted therapy. The group will focus on further specifying and piloting the AMP/ASCO/CAP guidelines (PMID: 27993330) for somatic variant classification and the diagnostic and therapeutic significance of NTRK fusions in cancers. After consensus classification, the panel will make these interpretations publicly available through the CIViC knowledgebase.